<DOC>
	<DOCNO>NCT00005918</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 2 form stavudine ( d4T ) . One form take day ( extended release ) form take twice day ( immediate release ) .</brief_summary>
	<brief_title>Effectiveness Safety Two Forms Stavudine HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize receive blind stavudine extend release ( d4T ER ) immediate release ( d4T IR ) formulation . Randomization balance screen HIV viral load le 30,000 copies/ml least 30,000 copies/ml site . Patients also receive open-label efavirenz ( EFV ) lamivudine ( 3TC ) . Efficacy evaluate 48 week dose period safety evaluate entire dosing period ( 56 week ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 18 year old . Patients live USA , Puerto Rico , Australia , Brazil , Singapore , Thailand least 12 year old ( need consent parent guardian 18 ) . Have viral load least 2,000 copies/ml within 21 day study entry . Have CD4 count least 100 cells/mm3 within 21 day study entry . Agree use barrier method birth control ( condom ) study . Are available followup least 56 week . Exclusion Criteria Patients eligible study : Are pregnant breastfeeding . Have take nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) 30 day within 14 day study entry . Have new opportunistic ( HIVrelated ) infection condition require treatment . Have acute ( early ) HIV infection . Have diarrhea ( least 6 loose stools/day least 7 day row ) within 30 day prior study entry . Abuse alcohol drug . Have active hepatitis within 30 day prior study entry . Have history peripheral neuropathy ( condition affect nervous system ) . Can take medication mouth . Are allergic certain antiviral drug . Need take certain medication take EFV . Have certain condition prior treatment might affect study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>efavirenz</keyword>
</DOC>